Since January 2006, 49 babies have died out of 4,142 who were enrolled in clinical trials at the All-India Institute of Medical Sciences in Delhi, a highly-regarded public hospital which provides care for low-income families. Although the mortality rate for the infants was lower than for the rest of the facility's patient population, 1.2% versus 4%, the number of children and the fact that most of them were less than one year old has provoked a political outcry.
Manish Tiwari, a Congress Party spokesperson, said: "the practice of using infants like guinea pigs for drug testing must end," in response to a report by the Uday Foundation for Congenital Defects and Rare Blood Groups, which compiled the data.
However, the AIIMS responded by noting that it was not clear how many of the infants had been given drugs and how many were in placebo or control groups. He told the UK's Times newspaper that "many of these babies were very ill."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze